Anticancer Drugs Market

Anticancer Drugs Market Outlook (2022-2032)

The global anticancer drugs market is set to enjoy a valuation of US$ 172.8 Billion in 2022 and further expand at a CAGR of 6.8% to reach US$ 335 Billion by the end of 2032. From 2017-2021 a CAGR of 6.1% was registered for the anticancer drugs market. The global sales of the anticancer drugs market in 2021 were held at US$ 160.9 Billion.

Anticancer drugs account for more than half of global spending on cancer treatment. With more emphasis on drugs, the share of anticancer drug treatment is likely to increase in collective spending on cancer treatment. Anticancer drugs are also known as antineoplastic drug which is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones

Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions in order to reduce the incidence level. North America is the expected to be the dominant regional anticancer drugs market for anticancer drugs in terms of revenues as well as drug discoveries.

Asia is expected to witness high growth in anticancer drug market, due to increasing government initiatives, rising economy and improvement in healthcare conditions in the region. Some of the key driving forces for anti-cancer drugs market in emerging countries are increasing R&D investment, large pool of patients and rising government funding.

Attributes	Details
Anticancer Drugs Market Size (2021A)	US$ 160.9 Billion
Estimated Market Value (2022E)	US$ 172.8 Billion
Forecasted Market Value (2032F)	US$ 335 Billion
Global Market Growth Rate (2022-2032)	6.8% CAGR
North America Market Share (2021)	~40%
Europe Market Growth Rate (2022-2032)	~6.6% CAGR
United States Market Growth Rate (2022-2032)	~7.7% CAGR
Key Companies Profiled	Hoffmann-La Roche Ltd Eli Lilly and Company Novartis AG Pfizer Inc Bayer AG AstraZeneca Takeda Pharmaceutical Company Limited Merck & Co., Inc. CELGENE CORPORATION Amgen Inc.

Sales Analysis of Anticancer Drugs (2017-2021) Vs. Market Forecast Outlook (2022-2032)

The global market for anticancer drugs expanded at a CAGR of 7.8% over the last five years (2017-2021). After infectious, parasitic, and cardiovascular diseases, cancer ranks third in terms of mortality worldwide. According to Fact.MR data, there were 9.5 million cancer deaths and 17.0 million new cancer diagnoses worldwide in 2021.

Simply because of population expansion and ageing, it is anticipated that by 2040 there would be 16.3 million cancer deaths and 27.5 million new cancer cases worldwide. Anticancer drugs have thus shown favorable growing traction during the course of historic period due to their efficacy in treating malignant or cancerous diseases.

The vendor landscape on the global market for anticancer drugs is very competitive. The market is fragmented due to some of the biggest pharmaceutical players in the world. Leading businesses compete in the market with cutting-edge products and robust pipelines, boasting high efficacy and efficiency.

Due to their emphasis on cutting-edge treatment techniques, the number of small players is also steadily increasing. Owing to above mentioned factors anticancer drugs market will see a good growth during the forecast period.

Fact.MR suggests that the global anticancer drugs market will be valued at US$ 335 Billion by 2032 end posing a CAGR of 6.8% since 2022.

• Short Term (2022 Q2 to 2025): Growing awareness of the benefits of anticancer drugs such improving survival rate and tumor progression will favorably affect the market growth.
• Medium Term (2025-2028): Increasing government initiatives and funding will propel the market growth of anticancer drugs in the later forecast years.
• Long Term (2028-2032): Growing demand for high-quality medical solutions will dictate the long term growth of anticancer drugs market across different regions.

Over the 2017-2021 historical period, the global anticancer drugs market registered a CAGR of 7.8%, and according to the Fact.MR, a market research and competitive intelligence provider, the market is projected to exhibit growth at a 6.8% CAGR between 2022 and 2032.

What’s Driving Demand for Anticancer Drugs?

Increasing Population Size and Cancer Incidence Rate to Drive the Sales of Anticancer Drugs

Painkillers such as morphine, acetaminophen, and nonsteroidal anti-inflammatory medications are frequently used by patients with lung, bone, and other malignancies. As more people are being diagnosed with the disease, there has been a considerable increase in the amount of money spent on cancer-fighting drugs. As a result, an increase in cancer incidences is anticipated to drive the market growth of anticancer medications.

The population of the world is expanding at a rate that has never been seen, especially when compared to younger age groups. By 2060, it is expected that there will be 95 million more Americans aged 65 and older than there are today, bringing the percentage in picture, it is going to increasing to roughly 23% of the population from 16%, suggests Fact.MR. As a result, it is anticipated that the ageing population would drive up demand for cancer control medications, fueling the market's expansion of target product.

Programs and Resources that Help with Cancer Related Expenses to Maintain Growth Trajectory of Anticancer Drugs Sales

The principal expenses associated with cancer diagnosis and treatment include hospital stays, doctor visits, medications, tests, procedures, and the services of medical experts. The majority of these expenses are reimbursed if patients are covered by insurance, managed care, or public health care programs. As a result, the target market is being helped to sustain its growth trajectory by the programs and resources that are available to help with cancer-related expenses.

Other important factors that are anticipated to drive the revenue growth of the anticancer drugs market include developing healthcare infrastructure and the shift in cancer risk from developed to developing countries as a result of factors like industrialization, sedentary lifestyles, and exposure to carcinogens.

Additionally, the market for anticancer medications has been driven to expand at a notable rate by increased awareness of early diagnosis and treatment. In addition, rising out-of-pocket healthcare costs in both developing and developed economies, as well as the establishment of sizable cancer specialist hospitals, are anticipated to support the expansion of the market for anticancer medications during the course of the assessment period.

What are the current restraining factors for the Antibody Drug Conjugates Contract market?

Exorbitant Costs of Anticancer Drugs Making It Unaffordable for Cancer Patients

Anticancer medications are created and sold in accordance with regulatory agency authorization, such as those from the US FDA and other organizations. Manufacturers must provide thorough clinical data to support the safety and efficacy of the product under test in order to receive approval for their product launches.

In order for the major players to remain competitive, these approval procedures are frequently drawn out and require significant financial input from them, which has a direct impact on the cost of the goods they create. The product's final pricing has been impacted by the high cost of production. As a result, the market for anticancer medications is constrained by financial toxicity, which imposes a significant cost burden on cancer patients.

Comparative View of Anticancer Drugs Markets

Anticancer Drugs Market :

Attributes	Anticancer Drugs Market
Growth Factor	Rising out-of-pocket healthcare costs in both developing and developed economies, as well as the establishment of sizable cancer specialist hospitals, are anticipated to drive the anticancer drugs market.
Opportunity	The technological advancement in healthcare is expected to provide opportunities for the growth of anticancer drugs market.

Cancer Antigens Market :

Attributes	Cancer Antigens Market
Growth Factor	The increasing prevalence of different types of cancer is anticipated to bring vital growth to the cancer antigen market.
Opportunity	The increased awareness, government funding, and funding by the various private organization towards cancer treatment and prevention are expected to increase the growth of the cancer antigens market.

Cancer Diagnostic Market :

Attributes	Cancer Diagnostic Market
Growth Factor	Increases in the prevalence and incidence of different forms of cancer, such as lung cancer and breast cancer, and improved imaging of dangerous cells, innovations in equipment to detect the kind of cancer, and an increase in the accuracy of the result would assist the cancer diagnostics market.
Opportunity	Increased diagnostics laboratory infrastructure in developed nations and increased usage of AI in cancer detection is projected to drive the market.

Country-wise Insights

Will Revenue Growth Keep the Momentum High for the North America Anticancer Drug Market?

The Rising Number of Cancer Patients in The United States Drives the High Demand for Anticancer Drugs.

The anticancer drugs market share in the United States is expected to reach at a CAGR of 7.7% from 2022 to 2032. Rising cancer cases, growing healthcare costs, high rates of cancer diagnostic testing, the availability of numerous cutting-edge cancer treatments, and the significant presence of top anticancer drug producers are all factors that are propelling expansion in the U.S. anticancer drugs market.

The number of cases of multiple cancer has increased dramatically in recent years in the United States, and this trend is anticipated to continue even throughout the anticipated time frame. The country's anticancer drug market share would also increase in the upcoming years owing to the increased R&D spending, rapid growth in the market for cancer supportive care goods, and an increase in the development and approval of new medications.

Why is Asia Pacific Prominent Market for Anticancer Drugs Contract?

Cost Effective and Quality Healthcare Service is Going to Drive the Asia Pacific Anticancer Drugs Market

Asia Pacific market accounted for 14.2% of global anticancer drugs market at the end of 2021. It is anticipated that increased government support and funding for market participants' R&D efforts will boost drug availability and, as a result, strengthen the pipeline in Asia Pacific region.

Another important element driving the expansion of the market for anticancer medications in the region is the ongoing improvements to the healthcare infrastructure.

Category-wise Insights

Which Drug Class of Anticancer Drugs is Most Widely Preferred?

Anticancer therapies Segment will dominate the segment during the Forecast Period

In order to offer improved anticancer treatments and dramatically shorten time to market, market participants are increasingly forming co-development partnerships. This is due to the rise in demand for anticancer therapies that have fewer side effects.

One such development is the use of targeted medicines, which operate just against cancer cells while being completely harmless to healthy cells. Thus, in 2021, the targeted therapy market category had a 58.6% market share of the entire market and was expected to grow at a CAGR of 6.8% from 2022 to 2032.

Based On Cancer Type Which Segment Accounts for the Highest Market Share?

The Rising Prevalence of Lung Cancer led to the Market Growth

The different types of cancer include prostate, lung, breast, melanoma, colon, rectum, and other types. Due to the high prevalence of lung cancer and the potential pipeline of non-small cell lung cancer therapies during the projection period, lung cancer is anticipated to grow at a CAGR of 6.4% over the forecast period.

Additionally, lung cancer is also one of the malignancies that develop most frequently in the world and is a major cause of mortality globally. This has a favorable effect on the market for the desired product.

Start-Ups for Anticancer Drugs Market

The new companies that have started to deal with the various kinds of anticancer drugs have been focussed at employing smart technologies to enhance productivity as well as efficiency in the field.

Some of the start-up companies operating in anticancer drug market are PV Pharma, Getwell Oncology, Amgen, Voxtur Bio Ltd. among others. Some of the recent developments of anticancer drugs market providers are as follows

• In October 2022 - Amgen announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer

Competitive Landscape

Prominent anticancer drugs manufacturers are Hoffmann-La Roche Ltd, AbbVie, Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Celgene Corporation, Amgen Inc.

The two main strategies used by the major players in the anti-cancer medicine business are the introduction of new products and acquisitions. A significant amount of market enthusiasm is being fueled by player collaboration on research and development as well as the FDA's fast-track approval for life-saving conditions.

• In December 2020, to find and create innovative treatments using E3 degraders against difficult-to-drug targets, AbbVie and Frontier Medicines, Crop. have formed cooperation.
• In January 2021, Bayer expanded its pipeline of prostate cancer treatments by entering into a pharmaceutical purchase agreement with Noria Therapeutics and PSMA Therapeutics.
• In October 2022 - Tavros Therapeutics and Vividion Therapeutics announced a strategic collaboration to discover and enhance targeted oncology programs
• In August 2022 - Bristol Myers Squibb announced that it has successfully completed its acquisition of Turning Point Therapeutics, Inc.

Segmentation of Anticancer Drugs Industry Research

• By Drug Class :

  • Cytotoxic
  • Hormonal Therapy
  • Targeted Therapy
    • Monoclonal antibodies
    • Small molecule inhibitors

• By Cancer Type :

  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer
  • Melanoma
  • Colon and Rectum Cancer
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & ASEAN
  • Oceania
  • Middle East & Africa